Breast screening debate can be settled only with high quality randomised controlled trial

Hackshaw notes the difficulty of instituting new high quality randomised controlled trials in breast screening.1 Instead, we are asked to consider other evidence, including the decrease in breast cancer mortality seen at about the same time that breast screening programmes were implemented. This evidence is particularly weak, considering all the other changes in …